This article reviews the current strategies and challenges of diagnosing pancreatic cystic lesions, and presents an overview of molecular tools that are available to enhance diagnostic accuracy. Specifically, we highlight the emergence of microRNAs (miRNAs) as diagnostic markers. miRNA signatures have been reported for both solid tissue and biofluid specimens, including cyst fluid, collected from patients with solid and cystic pancreatic lesions. These miRNA signatures offer the opportunity to improve molecular characterization of pancreatic lesions, to help guide clinical management through early diagnosis and informed prognosis, and to provide novel therapeutic targets for pancreatic cancer. 
Definitive characterization of these different types of pancreatic cystic lesions relies mainly on the combination of diagnostic imaging and analysis of cyst fluid obtained during endoscopic ultrasound-guided fine needle aspiration (EUSFnA). Unfortunately, the imaging findings of pancreatic cysts can be similar, making differentiation between benign and premalignant lesions difficult [3] [4] [5] [6] . In addition, current cyst fluid analyses fail to clearly distinguish among the different types of pancreatic cysts, thus preventing the prediction of their behavior [6, 7] . the accurate classification of pancreatic cysts is important since pre-malignant lesions may require surgical resection, while benign, non-malignant cysts can be monitored without the need for surgery. In this review we present an overview of pancreatic cystic neoplasms and discuss recent data supporting the potential clinical utility of miRnA profiling as an ancillary tool in diagnosis. of ScAs is not well described; however, they appear to grow over time. malignant transformation is extremely rare with only a few case reports of serous cystadenocarcinoma [11] . On pathology, ScAs are lined by glycogen-containing cuboidal epithelial cells ( Figure 1B ). ScAs are typically monitored with serial imaging due to their tendency to grow, although the frequency of imaging is debatable with some advocating imaging every 12 months while others suggest biennial surveillance [12] [13] [14] . Because these are benign lesions, surgical resection is reserved for patients with symptoms, cystic lesions without a clear diagnosis where the potential for malignancy cannot be ruled out, and large (>4 cm)
lesions.
mucinous cystic neoplasms are pre-malignant parenchymal lesions that almost exclusively occur in women, usually between 40 and 50 years old [10] . they arise in the body-tail of the pancreas in approximately 95% of patients and are defined by the presence
Differential Diagnosis
Sixty percent (60%) of pancreatic cystic lesions are cystic neoplasms (mostly composed of ScA, mcn, IPmn), 30%
are pseudocysts and approximately 10% are the result of degeneration of solid neoplasms [8] . Pseudocysts are sequelae of acute pancreatitis and require at least 4 -6 weeks to arise [9] . A thin capsule of non-epithelialized granulation or fibrotic tissue forms a wall around amylase-rich fluid. Symptoms, when present, typically consist of abdominal pain, but gastric outlet and/or biliary obstruction may occur as well.
Serous cystadenomas are benign pancreatic cystic neoplasms, which very rarely become malignant. ScAs account for over 30% of pancreatic cystic neoplasms and typically occur in women over the age of 60 [10] . ScAs are multicystic, and 30% have a lobular 'honeycomb' appearance due to dense septations producing multiple small cysts ( Figure 1A ). As with the majority of pancreatic cystic lesions, ScAs are often discovered type IPmn is 49% and 73%, respectively [18] . the mean risk of malignancy in mD-IPmn is 62% [16] , and the malignant potential of mixed type IPmn is believed comparable to this. therefore, surgical resection is recommended for all patients with mD-or mixed type IPmn who are surgical candidates [16] . However, nearly 20% of BD-IPmns originally diagnosed by radiology are later found by surgical pathology to be mixed type IPmns [18] . Because only approximately 15% of BDIPmns undergo malignant transformation [19] [16] . the previous criteria from 2006 also supported surgery for cyst size >3 cm [20] , however, the recent criteria deemphasize size as the sole criteria in the decision to operate and indicate to 'strongly consider' surgery in young, otherwise healthy patients with cysts >3 cm.
Patients who do not undergo surgical resection should be followed with surveillance imaging. A repeat ct or mRI with mRcP should occur 3-6 months following the initial imaging.
If the lesion appears stable, surveillance recommendations depend on cyst size ranging from every 3-6 months for cysts >3 cm to every year or other year for cysts <2 cm [16] .
Other less common pancreatic cystic neoplasms include solid pseudopapillary neoplasms (SPEns), which occur almost exclusively in young women of childbearing age and account for 1-2% of pancreatic cystic neoplasms. About 10-15% of SPEns are malignant, and to date, no predictors of aggressive behavior have been identified [21] . these patients usually present with nonspecific abdominal pain and occasionally with an abdominal mass palpable on examination. SPEns typically appear as a large well-defined encapsulated mass with peripheral solid component and cystic degeneration in the center with areas of hemorrhage (Figure 4) [22] . Pathology reveals characteristic pseudopapillae with cystic spaces containing hemorrhage and cholesterol clefts in myxoid stroma alternating with solid tissue.
All patients with SPEn should undergo surgical resection. Local invasion and/or limited metastases occur in less than 20% of patients with SPEn and are not a contraindication to surgical resection. Long-term survival is excellent for these patients with 5-year survival rates of 95% [22] .
Less commonly observed lesions such as neuroendocrine or acinar cell tumors occasionally undergo cystic degeneration. cystic neuroendocrine tumors account for only 8% to 17% of pancreatic neuroendocrine tumors and are usually asymptomatic [23] . Acinar cystadenocarcinoma is extremely rare with fewer than 10 cases reported in the literature. these tumors typically present with abdominal pain and a multilocular cystic lesion [24] . of ovarian-like stroma ( Figure 2A ) [10] . mcns usually appear smooth, well-defined, and unilocular or with a few septations ( Figure 2B ). Unlike ScAs, presence of symptoms in mucinous cystic lesions is associated with malignancy. Features that are risk factors for malignancy in mcn include older age (> 55 years), large size (diameter >6 cm), and presence of thick cyst wall, mural nodules, or peripheral eggshell calcification [10] . the true incidence of malignancy in mcns is unknown. Recent studies suggest incidence rates of invasive cancer can range from 12% to 29% with only 5.5% carcinoma in situ [15] . the pre-malignant nature of mcns combined with the lack of reliable tools to definitively diagnose malignancy in mcns preoperatively and the relatively young age (40-50 years) of these patients drives consensus recommendations for surgical resection of these lesions in all cases. Patients who are poor surgical candidates may be followed with serial imaging and monitored for symptoms [16] . with filling defects. Pancreatoscopy, which involves direct endoscopic visualization within the pancreatic duct using special instruments, can be helpful in differentiating mD-IPmn from chronic pancreatitis by visualizing intraductal tumor [37] [38] [39] . Similarly IDUS with the insertion of a tiny ultrasound probe into the pancreatic duct can aide in diagnosis of mD-IPmn with identification of the frond-like tumor within the duct [40] .
Cyst Fluid Analysis
Imaging alone whether by radiology or EUS is often inadequate to accurately characterize pancreatic cystic lesions. With advances in endoscopy allowing the safe sampling of pancreatic cyst fluid via EUS-FnA [41] , collection of cyst fluid for analysis for various biochemical markers, DnA markers, and cytology has become more routine. this is important because cytology alone is generally non-diagnostic, with most studies demonstrating less than 50% sensitivity for diagnosis of the cyst lesion [7, [42] [43] [44] , and at best allowing differentiation between mucinous and
Execution of the appropriate treatments as outlined above requires the definitive diagnosis of each type of pancreatic cyst.
Unfortunately, a major problem with managing pancreatic cystic lesions is that often, despite extensive radiologic and endoscopic evaluation, the detailed diagnosis of the lesion remains unclear [25] . the most cost-effective approach to asymptomatic patients with incidentally discovered pancreatic cystic lesions requires the consideration of each patient's age, cyst location, cyst size, and preoperative health score (as defined by the American Society of Anesthesiologists) [26] . three management options were evaluated in a recent study to determine which was most cost-effective: a conservative approach with radiologic followup, an aggressive approach with surgical resection for all surgical candidates, or a EUS-directed approach. the EUS approach was the most cost-effective strategy, with subsequent decision for radiologic follow-up or surgery based on a combination of cytology and cEA from EUS-FnA in addition to the patient's surgical risk.
current Diagnostic tools

Radiologic Imaging
Evaluation of pancreatic cysts includes a combination of radiologic imaging, endoscopic ultrasound, and cyst fluid analyses. For radiologic characterization of pancreatic cysts, patients typically undergo a "pancreatic protocol" abdominal ct scan and/or mRI [27] . mRI is preferred over ct scans, with its enhanced ability to detect septa, nodules, and ductal communication [27] . magnetic resonance cholangiopancreatography (mRcP) is superior to ct in characterizing IPmn by demonstrating ductal communication, main duct involvement, and small branch duct cysts (table 2) [28]. Furthermore, recent concern over radiation exposure from repeated ct may favor the use of mRI for surveillance of pancreatic cysts [29] . Overall accuracy of radiologic imaging for the histologic diagnosis of pancreatic cysts is about 40%
to 60% [30] [31] [32] , while both ct and mRI predict the presence of malignancy in pancreatic cysts with 73% to 79% accuracy [32, 33] .
Endoscopic Imaging
Both mRI and EUS have modest sensitivity (58% to 67%) for detecting mural nodules and both have historically demonstrated approximately 51% accuracy for diagnosing mucinous lesions [34] . However, a recent study refined the EUS criteria for differentiating mucus from a nodule, and improved diagnostic accuracy in the detection of these EUS criteria to 79% [35] .
mRI and EUS may be complementary techniques, and used in combination may potentially increase diagnostic yield for mucinous cysts [36] . Few cyst fluid markers have proven valuable and none are definitively diagnostic (tables 2 and 3). cEA is the most extensively studied and allows the differentiation of mucinous and non-mucinous cystic lesions. Although elevated cEA is consistent with a mucinous cyst, the cutoff level remains debated; studies use cutoff levels from 110 to 800 ng/mL [46] . In addition, cEA cutoffs can vary depending on the laboratory performing the assay. the higher the cEA, the greater the specificity while sensitivity is sacrificed. the commonly used cutoff of 192 ng/mL yields modest sensitivity (73%) and specificity (84%) [34] . cEA less than 5 ng/mL is 95% specific for a ScA or pseudocyst. cyst fluid amylase lower than 250 units/L can exclude a pseudocyst with 98% specificity and 44% sensitivity [46] . A recent study in surgically resected IPmn concluded that serum biomarkers, such as cA 19-9 and cEA, may be helpful in predicting invasive carcinoma within IPmn [47] .
clinical utility of molecular DnA markers in cyst fluid has been a strong focus in diagnosing malignant pancreatic cystic lesions.
A peer-reviewed multicenter study suggested high specificity (96%) for malignancy when high amplitude k-ras mutation was followed by allelic loss, but very low sensitivity (37%) [48] . this same mutation pattern showed perfect specificity for diagnosing a mucinous cystic lesion; however its sensitivity was lacking (19%).
Presence of k-ras mutation alone had 96% specificity and 45% sensitivity for detecting mucinous lesions. the conclusion of this study was that in the presence of these mutations, the likelihood that the cyst is malignant and mucinous is high; however, their absence is not helpful in ruling out the malignancy or the presence of a mucinous cyst. thus, better biomarkers are necessary to diagnose both malignant and mucinous pancreatic cystic lesions. microvesicles (~100 nm-1 µm in diameter), and exosomes (~30-100 nm), which protect them from degradation [73] [74] [75] [76] [77] [78] .
Initial reports indicate that circulating miRnAs could participate in cell-to-cell communication [79] [82] .
Although the results described above are tantalizing, most of the data come from single-institution studies. Several elements must be considered to ensure successful clinical validation of promising miRnAs initially discovered in any biofluid specimen, as evidenced by promising lung cancer miRnAs [83] . Some of the most significant confounding factors may include choice of sample type (e.g. whole blood, serum, and plasma), sample numbers, study design, sample collection method, sample storage and shipment, and others. Hence, all results must be validated in multi-center, appropriately powered prospective studies with protocols emphasizing biomarker normalization, quality control and SOP standardization before they can be applied in the management of patients with pancreatic cancer.
Therapeutic miRNA candidates
In addition to aiding in diagnosis and prognosis of PDAc, a greater understanding of the aberrant expression of specific miRnAs in various pancreatic lesions may advance therapeutics.
Down-regulation of miR-21 in cell cultures led to increased cell death when treated with gemcitabine [84] . Analogously, overexpression of miR-21 resulted in increased cell proliferation and chemoresistance to gemcitabine [85] . Another clinical study found that patients with high expression levels of miR-21 in their tumor tissue had decreased overall survival both in the metastatic accuracy, precision, analytical sensitivity, and specificity. the diagnostic potential of miRnAs was first realized in a LDt, the miRInform  Pancreas (Asuragen), which differentiates PDAc from normal and chronic pancreatitis tissue using formalin fixed paraffin embedded specimens [50] . of miR-21, miR-221, and miR-17-3p were able to differentiate the mucinous cysts from those the non-mucinous specimens with p < 0.01 [92] . the key candidate, miR-21, was able to resolve those diagnostic entities with a median specificity of 76% and a sensitivity of 80%. Recently, matthaei et al. used cyst fluid specimens collected in the operating room to build a 9-miRnA classifier, which predicted the degree of dysplasia within the epithelial lining of an IPmn and identified cysts that likely needed surgical resection [93] .
this classifier consisted of miR-18a, miR-24, miR-30a-3p, miR92a, miR-342-3p, miR-99b, miR-106b, miR-42-3p, and miR-532-3p, and predicted with 89% sensitivity and 100% specificity which cyst fluid specimen came from a cyst requiring resection vs. a more conservative management. Other studies of surgical pathology specimens found miRnAs that were down-regulated in PDAc compared to serous cystadenoma (e.g. miR-21) and up-regulated in IPmn and PDAc (e.g. miR-196a and miR-183) relative to normal pancreatic tissue [94, 95] .
Our own exploratory work on surgically resected pancreatic cyst specimens has revealed several miRnA models that can accurately differentiate serous cystadenoma, mucinous cystic neoplasm, and IPmns [3] . Specifically, we identified four different 4-miRnA models, which distinguished with high degree of accuracy: 1/ mcn from ScA, IPmn, and PDAc; 2/ ScA from mcn, IPmn, and PDAc; 3/ PDAc from IPmn; 4/ mcn from BD-IPmn. Further studies are needed to examine the ability of miRnA to identify the various cystic lesions using cyst fluid specimens. Such a transition will require appropriately powered prospective studies with specimens collected from consecutive patients, stored in a standardized manner, and equivalently monitored for quality control. Additionally, most of those lesions would be required to have undergone surgical resection to achieve the gold standard diagnosis, which will necessitate a multicenter effort. We believe that a combination of the top candidate biomarkers identified in resected tissues with those and in the adjuvant setting, along with increased gemcitabine resistance [86] . Similarly, surgically resected patients with low miR-21 expression levels demonstrated increased survival with adjuvant chemotherapy [87] . miR-142-5p, miR-204, miR-221, and miR-10b are among other miRnAs with a potential therapeutic role in PDAc [88] . A study reported that low levels of miR-10b in FnA samples collected from patients who underwent neoadjuvant therapy were associated with improved response to gemcitabine-based neoadjuvant therapy, longer time to metastasis and improved overall survival of 50% after 2 years [52] . It appears that miR-10b expression levels could be used as an indicator of localized pancreatic disease, similarly to miR-143 which was negatively correlated with lymph nodes spreading (r = -0.64; P = 0.0004) [89] . two groups reported miRnA signatures that showed utility in predicting survival in patients with nodal disease. the miRnAs in these signatures did not overlap and included: miR-452, miR-105, miR-127, miR-518a-2, miR-187 and miR-30a-3p [55] , as well as miR-155, miR-203, miR-210 and miR-222 [66] . modulating expression levels of various miRnAs may promote apoptosis of cancer cells and provide targeted therapy for PDAc [90] .
miRnA in Pancreatic cysts
While efforts continue to better diagnose, prognosticate, and treat PDAc, much attention has focused on pancreatic cystic neoplasms, which may be precursors to PDAc. As described earlier, diagnosis and prediction of behavior of pancreatic cystic lesions is currently difficult and limited. the solution to this clinical dilemma may be provided by the application of miRnA analysis on preoperatively collected specimens, such as pancreatic juice and cyst fluid. For example, expression of miR-155 was shown to be elevated in 60%
IPmn pancreatic juice specimens as compared to disease-free controls [91] . In pancreatic cystic fluid, elevated expression levels identified in cyst fluid specimens may provide an opportunity for improved molecular characterization of cystic lesions. Figure 6 shows hypothetically how these models may be used clinically.
Larger studies will also be needed to examine the ability of relative expression levels of various miRnAs to differentiate among the different degrees of dysplasia in mucinous lesions.
conclusions
Despite improved imaging modalities and increasing clinical awareness of pancreatic cysts, there is currently no preoperative diagnostic assay that has sufficient sensitivity and specificity to accurately predict the biological behavior of a pancreatic cyst.
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